Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camcevi (LMIS 25 mg) in Prostate Cancer
NCT03261999Phase 3Completed
- Sponsor
- Foresee Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Nov 2018
- Modality
- Peptides, Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of leuprolide in prostate cancer (PCa), sponsored by Foresee Pharmaceuticals. Primary endpoint: Percentage of subjects with serum testosterone concentration suppressed to castrate levels (<= 50 ng/dL). Started Sep 2017; status: completed.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03261999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03261999.